NKTX

Nkarta, Inc.

Healthcare
Biotechnology
$208M market cap

Forecast run · Sep 14, 2026Upside rank 696 of 3,136

Model Signal

ForecastQ Daily Probabilities

51.3%

43.5%

33.9%

Analyst Consensus

Recommendation2.08/5 Buy

Last price$2.91

Price target$9.00

Implied move+209.3%

Analysts12

ForecastQ Portfolios

NKTX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.